Investment Rating - The report maintains an "Overweight" rating for the industry [2] Core Insights - The Alzheimer's Disease (AD) sector is transitioning from "symptom improvement" to "disease-modifying therapies (DMT)" in 2026, marking a critical growth phase with the approval of two major amyloid-beta (Aβ) antibody drugs and the emergence of new diagnostic technologies [4][11] - 2026 is expected to be a pivotal year for AD, with significant conferences serving as platforms for academic exchange and market negotiations, focusing on drug administration convenience, the rise of Chinese voices, and the reassessment of diagnostic value [15] - Key drug progress in 2026 includes regulatory decisions on AXS-05 and Leqembi, which could expand the AD treatment market significantly [17] - The AD detection field is set for large-scale clinical adoption, driven by blood tests, AI advancements, and new biomarkers, with a focus on early and precise diagnosis [19] Summary by Sections Industry Overview - The industry comprises 504 listed companies with a total market value of approximately 69,490.56 billion [2] Market Trends - The investment logic is shifting from solely "new drug development" to a comprehensive ecosystem of "early screening + precise treatment + full-course management" [4][11] Key Drug Developments - Major drug approvals and data releases are anticipated throughout 2026, including AXS-05 and Leqembi, which are crucial for market expansion [17][18] Diagnostic Innovations - The trend towards "blood-based" and "intelligent" diagnostics is accelerating, with significant advancements expected in blood biomarkers and AI integration in imaging [19][20] Investment Opportunities - The report highlights the increasing role of Chinese pharmaceutical companies in the global AD landscape, with notable collaborations and innovative drug developments [21][22] Clinical Trials and Research - The domestic clinical pipeline for AD is entering a phase of rapid development, with a focus on precision diagnostics and disease-modifying treatments [24]

证券代码：688105 证券简称：诺唯赞 公告编号：2026-006 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、回购股份的基本情况 南京诺唯赞生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 19 日 召开第二届董事会第十七次会议，审议通过了《关于以集中竞价交易方式回购公 司股份方案的议案》，同意公司以不低于人民币 500 万元（含）且不超过人民币 1,000 万元（含）的自有资金，通过集中竞价交易方式回购公司已发行的部分人 民币普通股（A 股）股票，用于实施股权激励或员工持股计划，回购价格不超过 人民币 30 元/股（含），回购期限为自公司董事会审议通过本次回购股份方案之日 起 12 个月内。具体内容详见公司于 2025 年 6 月 20 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于以集中竞价交易方式回购公司股份方案的公告》 《关于以集中竞价交易方式回购公司股份的回购报告书》（公告编 ...

南京诺唯赞生物科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体请以南京诺唯赞生物 科技股份有限公司（以下简称"公司"）2025年年度报告中披露的财务数据为准，提请投资者注意投资风 险。 证券代码：688105证券简称：诺唯赞 公告编号：2026-005 一、2025年度主要财务数据和指标 单位：元 币种：人民币 2、影响经营业绩的主要因素 报告期内，公司生物制品类产品的增值税税率由3%调整至13%，对整体营收与盈利产生较大不利影 响。因未达成2023年限制性股票激励计划相关归属期业绩考核目标，公司于报告期末冲回对应归属期前 期已计提的股份支付费用。同时，公司基于谨慎性原则，冲回部分前期已确认的递延所得税资产，所得 税费用相应增加。 其他综合影响本报告期经营业绩的主要因素包括：公司积极拓展创新业务与海外市场，相关销售费用同 比增长；公司持续加强费用预算管理，不断提升研发与运营效率，剔除部分股份支付费用冲回影 ...

Core Viewpoint - The company reported its 2025 annual performance, showing a slight decline in revenue and net profit, primarily impacted by tax rate changes and performance-related adjustments [1] Financial Performance - The company achieved operating revenue of 1.378 billion yuan, remaining stable compared to the same period last year [1] - The net profit attributable to the parent company was -16.97 million yuan, and the net profit after deducting non-recurring gains and losses was -79.36 million yuan, both showing a reduction in losses compared to the previous year [1] Tax and Regulatory Impact - The value-added tax rate for the company's biological products increased from 3% to 13%, significantly adversely affecting overall revenue and profitability [1] Stock Incentive Plan - The company reversed previously accrued share-based payment expenses due to not meeting the performance assessment targets of the 2023 restricted stock incentive plan [1] - Additionally, the company, based on a principle of prudence, reversed part of the previously recognized deferred tax assets, leading to an increase in income tax expenses [1]

Core Viewpoint - The company reported its 2025 annual performance, showing stable revenue but a net loss, primarily impacted by tax rate changes and performance-related adjustments [1] Financial Performance - The company achieved an operating revenue of 1.378 billion yuan, which is approximately flat compared to the same period last year [1] - The net profit attributable to the parent company was a loss of 16.97 million yuan, while the net profit after deducting non-recurring gains and losses was a loss of 79.36 million yuan, both showing a reduction in losses compared to the previous year [1] Tax and Regulatory Impact - The value-added tax rate for the company's biological products increased from 3% to 13%, significantly adversely affecting overall revenue and profitability [1] Stock Incentive Plan - The company did not meet the performance assessment targets related to the 2023 restricted stock incentive plan, leading to a reversal of previously accrued share-based payment expenses at the end of the reporting period [1] Deferred Tax Assets - Based on a principle of prudence, the company reversed part of the previously recognized deferred tax assets, resulting in an increase in income tax expenses [1]

证券日报网讯 2月26日，诺唯赞发布2025年度业绩快报公告称，2025年度公司实现营业总收入1，377， 881，284.80元，与上年同期基本持平；归属于母公司所有者的净利润为-16，970，222.17元。 （文章来源：证券日报） ...

Core Viewpoint - The company reported its 2025 annual performance, showing stable revenue but a net loss, primarily impacted by tax rate changes and performance-related adjustments [1] Financial Performance - The company achieved operating revenue of 1.378 billion yuan, which is approximately flat compared to the same period last year [1] - The net profit attributable to the parent company was a loss of 16.97 million yuan, while the net profit after deducting non-recurring gains and losses was a loss of 79.36 million yuan, both showing a reduction in losses compared to the previous year [1] Tax and Financial Adjustments - The VAT rate for the company's biological products increased from 3% to 13%, significantly adversely affecting overall revenue and profitability [1] - Due to not meeting the performance assessment targets for the 2023 restricted stock incentive plan, the company reversed previously accrued share-based payment expenses at the end of the reporting period [1] - The company also reversed part of the previously recognized deferred tax assets based on a principle of prudence, leading to an increase in income tax expenses [1] Operational Factors - The company actively expanded its innovative business and overseas markets, resulting in a year-on-year increase in related sales expenses [1] - The company continued to strengthen budget management, improving research and operational efficiency, with a slight year-on-year decrease in research and management expenses after excluding the impact of reversed share-based payment expenses [1]

证券代码：688105 证券简称：诺唯赞 公告编号：2026-005 南京诺唯赞生物科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体请以南京诺唯赞生物科技股份有限公司（以下简称"公司"）2025年年度报 告中披露的财务数据为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 二、经营业绩和财务情况说明 1 单位：元 币种：人民币 证券代码：688105 证券简称：诺唯赞 公告编号：2026-005 （一）经营情况、财务状况及影响经营业绩的主要因素 1、经营情况与财务状况 | 项目 | 本报告期 | 上年同期 | 增减变动 | | --- | --- | --- | --- | | | | | 幅度（％） | | 营业总收入 | 1,377,881,284.80 | 1,377,898,264.65 | 0.00 | | 营业利润 | -40,483,707.41 | -61,393,02 ...

诺唯赞公告称，2025年公司实现营业收入13.78亿元，与上年同期基本持平；归属于母公司所有者的净 利润为 -1697.02万元，扣除非经常性损益的净利润为 -7936.03万元，均较上年同期减亏。报告期末，总 资产49.20亿元，较期初下降2.56%；归属于母公司的所有者权益37.96亿元，较期初下降3.79%。业绩受 增值税税率调整、冲回股份支付费用和递延所得税资产等因素影响。 ...

Group 1 - Core viewpoint: NuoVance is actively participating in Alzheimer's disease research and has established strategic partnerships to enhance early diagnosis and treatment [1][2] - NuoVance participated in an academic conference on plasma biomarkers for Alzheimer's disease, contributing to multi-center research in the Northwest [1] - The company has formed a strategic cooperation with Taikang Medical to develop a new ecosystem for Alzheimer's prevention and treatment, focusing on the application of blood biomarkers in grassroots settings [1] Group 2 - As of February 12, 2026, NuoVance's stock price was 20.90 yuan, reflecting a decrease of 0.76% on that day, with a trading volume of 15.72 million yuan [2] - Over the past five days, the stock has seen a cumulative decline of 0.43%, with a narrowing fluctuation range of 1.09% [2] - Recent capital flow indicates a net inflow of 71,100 yuan from institutional investors on February 11 and a net inflow of 810,500 yuan on February 12, while retail investors showed a net outflow [2]